Sign in
WithdrawnPhase 2

A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas

Key facts

Who runs it
University of Michigan Rogel Cancer Center
Where
Ann Arbor, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 2
Started
Oct 2019
Ended
Oct 2025
Type of study
Interventional
Treatments tested
  • Panobinostat
  • Everolimus
Record updated
19 August 2019
Why it stopped
low accrual

Who can take part

Age
2 years to 30 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (28)Hide the full registry criteria

Who can take part

  • All patients and/or a legal guardian must sign institutionally approved written informed consent and assent documents
  • Patient must be greater than 2 years and less than 30 years
  • BSA (body surface area) greater than 0.3 m2
  • Functional status: Karnofsky > 50% for patients > 16 years of age and Lansky > 50% for patients < 16 years of age (Karnofsky and Lansky is a scoring system used to quantify the general well being of cancer patients where 100% represents perfect health and 0% represents death). Neurologic deficits in patients with CNS tumors must have been relatively stable for a minimum of 7 days. Patients who are unable to walk because of paralysis, but who are able to sit in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
  • Adequate bone marrow function
  • Adequate liver function
  • Adequate renal and metabolic function
  • Urine protein:creatinine (UPC) ratio of < 1; or a urinalysis that is negative for protein; or 24-hour urine protein level < 1000 mg/dL
  • Patients must have Magnesium > 1.5 mg/dL and potassium > 3.5 mmol/L
  • Patients with known seizure disorder must have seizures adequately controlled with non- enzyme inducing antiepileptic medications
  • No increase in steroid dose within the past 7 days
  • STRATUM A: histological confirmation of a newly diagnosed high-grade glioma or DIPG or STRATUM B: histological confirmation of a recurrent or progressive grade II-IV glioma (including DIPG) [histology can come from tissue at diagnosis or relapse]
  • Primary brain or spine tumor are eligible, including tumors with metastases, multiple lesions
  • Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy
  • Myelosuppressive chemotherapy: Must not have received within 3 weeks (6 weeks if prior nitrosourea)
  • Hematopoietic growth factors: At least 7 days since the completion of therapy with a growth factor, 14 days for long-acting (e.g. PEG-filgrastim)
  • Biologic (anti-neoplastic agent): At least 7 days or 3 half-lives (whichever is longer) since the completion of therapy with a biologic agent
  • Radiation therapy: Strata A: ≥ 2 weeks and ≤ to 12 weeks must have elapsed from radiation. Strata B: ≥ 2 weeks must have elapsed from focal radiation
  • Surgery: > 3 weeks from major surgery. If recent craniotomy, adequate wound healing must be determined by neurosurgical team
  • Autologous Stem Cell Transplant or Rescue: No evidence of active graft vs. host disease and ≥ 4 weeks must have elapsed
  • H3K27M mutation: Participants must have a mutation in H3.3 K27M or H3.1 K27M as identified by tumor (FFPE or fresh, diagnosis or relapse tissue, but relapse tissue preferred) sequencing, or by CLIA-certified immunohistochemistry staining positive for H3K27M, as defined by review by U of M neuro-pathology

Who cannot take part

  • Other medications: Patients receiving other anti-neoplastic agents are excluded; patients on enzyme-inducing anticonvulsive agents are excluded; patients requiring strong CYP3A4 or PGP inducers or inhibitors are excluded; patients on steroids for symptom management must be on a stable dose for 7 days prior to start of treatment
  • Allogeneic stem cell transplant: Patients within 1 year of allogeneic stem cell transplant, patients with active GVHD or requiring immunosuppression are excluded
  • Previous hypersensitivity to rapamycin or rapamycin derivatives
  • Patients with uncontrolled infection are excluded
  • Baseline QTc of >450 msec on EKG OR electrolyte imbalance predisposing to QTc prolongation (baseline ≥ Grade 1 hypokalemia or hyperkalemia; and baseline ≥ Grade 2 Ca++, Mg++, phosphate abnormalities). Repletion/correction is allowed to achieve eligibility. Use of QTC prolonging medications will be monitored throughout the trial
  • Patients who are breastfeeding, pregnant or refuse to use an effective form of birth control are excluded. Abstinence is considered an effective form of birth control
  • Inability to swallow oral pill (panobinostat does not have liquid formulation)

Where in United States

  • University of Michigan Cancer CenterAnn Arbor, United States

About the trial

What the trial wants to find out

This phase 2 trial will evaluate the activity of Panobinostat in combination with Everolimus for children with gliomas harboring H3.1 or H3.3K27M mutation, including newly diagnosed high-grade glioma or DIPG (diffuse intrinsic pontine glioma) after radiation (stratum A) and recurrent/progressive glioma (grade II-IV, including DIPG) (stratum B).

The group in the trial

  • Panobinostat and EverolimusTreatment being tested

    Panobinostat daily M, W, F for 2 weeks every 28 days for the first cycle (28 days). After first cycle Panobinostat daily M, W, F for 2 weeks every 28 days combined with Everolimus daily.

    Treatment: Panobinostat and Everolimus

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 2 Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas Harboring H3.3 or H3.1 K27M Mutation
Record updated
19 August 2019